Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;17(13):1611-1624.
doi: 10.2217/fon-2020-1032. Epub 2021 Feb 26.

Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases

Zeynep Oruç  1 , M Ali Kaplan  1 , Mustafa Karaağaç  2 , Neslihan Özyurt  3 , Ali Murat Tatlı  4 , Ali Osman Kaya  5 , Serkan Menekşe  6 , Engin Kut  6 , Sinan Koca  7 , Özlem Nuray Sever  8 , İrem Yasin  9 , Senar Ebinç  1 , Esra Zeynelgil  10 , Abdullah Sakin  11 , Nazım Serdar Turhal  12 , Abdurrahman Isikdogan  1
Affiliations

Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases

Zeynep Oruç et al. Future Oncol. 2021 May.

Abstract

Aim: To assess the efficacy and tolerability of the first-line treatment options for hormone-refractory prostate cancer patients with visceral metastases. Materials & methods: The records of 191 patients diagnosed with hormone-refractory prostate cancer with visceral metastases were analyzed retrospectively. Results: Docetaxel was administered to 61.2% (n = 117), abiraterone to 14.2% (n = 27) and enzalutamide to 9.4% (n = 18) as the first-line treatment. The median survival of the patients receiving docetaxel, abiraterone and enzalutamide as the first-line treatment during the hormone-refractory period was 15 (95% Cl: 12.9-17) months, 6 (95% Cl: 1.8-10.1) months and 11 (95% Cl: 0.9-23.1) months (p = 0.038), respectively. Conclusion: The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival.

Keywords: hormone-refractory disease; prostate cancer; visceral metastasis.

Plain language summary

Lay abstract The optimal therapeutic option for castration-resistant prostate cancer (CRPC) patients with visceral metastases is unknown. We assessed the efficacy and tolerability of the first-line treatment options for CRPC patients with visceral metastasis. One hundred ninety-one patients diagnosed with CRPC with visceral metastases were included in the study. The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival between first-line docetaxel, abiraterone and enzalutamide treatments in CRPC patients with visceral metastases. For patients who cannot undergo chemotherapy, enzalutamide, among novel androgen pathway inhibitors, may be the most appropriate option, given its numerical, although statistically insignificant, difference in overall survival and its fewer side effects compared with abiraterone.

PubMed Disclaimer

MeSH terms

LinkOut - more resources